Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2025-09-09 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Regulatory Filings Classification · 1% confidence The document is a short notification from Enlivex Therapeutics Ltd filed via the MAGNA system. It explicitly states 'Attached hereto is a report on 6k' and provides a filename '6k09092025_isa.pdf'. According to the 'Menu vs Meal' rule, since this is a short announcement stating that a report is attached rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-09-09 English
Presentation- PHASE IIA TOPLINE RESULTS
Investor Presentation Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It explicitly states that the company is furnishing an 'updated investor presentation' as Exhibit 99.1. The content following the cover page is a slide deck detailing clinical trial results (Phase IIa Topline Results), market potential, and company strategy. Since the document is a formal SEC filing (Form 6-K) that serves as the vehicle to distribute an investor presentation, it is classified as an Investor Presentation (IP).
2025-08-18 English
Presentation- PHASE IIA TOPLINE RESULTS
Regulatory Filings Classification · 1% confidence The document is a short notification from Enlivex Therapeutics Ltd filed via the MAGNA system. It explicitly states 'Attached hereto is a report on 6k' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, since this is a short announcement stating that a report is attached rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-08-18 English
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains a press release announcing positive topline clinical trial data for a medical product. While it is a regulatory filing, it does not fit into specific categories like 10-K, IR, or ER (as it is a clinical trial update, not a quarterly financial earnings release). Therefore, it falls under the fallback category for general regulatory announcements.
2025-08-18 English
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
Regulatory Filings Classification · 1% confidence The document is a short, standardized filing from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6k' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, since this is a short announcement notifying the public that a report (Form 6-K) is attached, it is classified as a Report Publication Announcement (RPA).
2025-08-18 English
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filing submitted to the SEC by Enlivex Therapeutics Ltd. The primary purpose of this filing is to announce an upcoming webinar to discuss clinical trial results. While it contains a press release as an exhibit, the document itself serves as a regulatory notification of a corporate event (the webinar) rather than the actual financial report or the clinical data itself. Given that it is a standard SEC filing used to announce corporate developments, it falls under the RNS (Regulatory Filings) category.
2025-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.